CoChat

Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma

Open access

Published version of a preprint

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

Purpose: For primary melanomas, tumor thickness, mitotic rate, and ulceration are well-laid cornerstones of prognostication. However, a molecular exposition of melanoma aggressiveness is critically missing. We recently uncovered a four-class structure in metastatic melanoma, which predicts outcome and informs biology. This raises the possibility that a molecular structure exists even in the early stages of melanoma and that molecular determinants could underlie histophenotype and eventual patient outcome. Experimental Design: We subjected 223 archival primary melanomas to a horizontally integrated analysis of RNA expression, oncogenic mutations at 238 lesions, histomorphometry, and survival data. Results: Our previously described four-class structure that was elucidated in metastatic lesions was evident within the expression space of primary melanomas. Because these subclasses converged into two larger prognostic and phenotypic groups, we used the metastatic lesions to develop a binary subtype-based signature capable of distinguishing between “high” and “low” grade forms of the disease. The two-grade signature was subsequently applied to the primary melanomas. Compared with low-grade tumors, high-grade primary melanomas were significantly associated with increased tumor thickness, mitotic rate, ulceration (all P < 0.01), and poorer relapse-free (HR = 4.94; 95% CI, 2.84–8.59), and overall (HR = 3.66; 95% CI, 2.40–5.58) survival. High-grade melanomas exhibited elevated levels of proliferation and BRCA1/DNA damage signaling genes, whereas low-grade lesions harbored higher expression of immune genes. Importantly, the molecular-grade signature was validated in two external gene expression data sets. Conclusions: We provide evidence for a molecular organization within melanomas, which is preserved across all stages of disease. Clin Cancer Res; 18(15); 4026–36. ©2012 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-12-0343

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 116

Metadata

Authors
Harbst, K., Staaf, J., Lauss, M., Karlsson, A., Måsbäck, A., Johansson, I., Bendahl, P.-O., Vallon-Christersson, J., Törngren, T., Ekedahl, H., Geisler, J., Höglund, M., Ringnér, M., Lundgren, L., Jirström, K., Olsson, H., Ingvar, C., Borg, Å., Tsao, H., & Jönsson, G.
Affiliations
  • Harvard University (US)
  • Authors' Affiliations: 1Department of Oncology, Clinical Sciences; 2CREATE Health Strategic Center for Clinical Cancer Research, Departments of 3Pathology and 4Surgery, Lund University, Lund, Sweden; 5Department of Oncology, Akershus University Hospital, University of Oslo, Norway; 6Department of Dermatology, Harvard Medical School; and 7Wellman Center for Photomedicine, MGH Cancer Center, Massachusetts General Hospital, Boston, Massachusetts
Corresponding author
Tsao, Hensin
Venue
Clinical Cancer Research
Published
2012-07-30
Volume
18
Issue
15
Pages
4026-4036
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2149635248
Cited by
105
References
22
Citations by year
2025: 2 · 2024: 4 · 2023: 4 · 2022: 2 · 2021: 7 · 2020: 7 · 2019: 10 · 2018: 12 · 2017: 11 · 2016: 7 · 2015: 17 · 2014: 16 · 2013: 5 · 2012: 1
FWCI
6.12
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
National Cancer Institute (K24CA149202, P50CA093683)
Topics
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
primary melanoma, molecular subtypes, tumor grade, prognostic signature, metastatic melanoma, histomorphometry, tumor thickness, mitotic activity, ulceration, immune-related genes, proliferation genes, relapse-free survival, overall survival, gene expression profiling
MeSH terms
Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Melanoma, Middle Aged, Mutation, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Gene Expression Regulation, Neoplastic, BRCA1 Protein, Gene Expression Profiling, Kaplan-Meier Estimate, Young Adult, Neoplasm Grading

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-12-0343
The paper
Harbst, K., Staaf, J., Lauss, M., Karlsson, A., Måsbäck, A., Johansson, I., Bendahl, P.-O., Vallon-Christersson, J., Törngren, T., Ekedahl, H., Geisler, J., Höglund, M., Ringnér, M., Lundgren, L., Jirström, K., Olsson, H., Ingvar, C., Borg, Å., Tsao, H., & Jönsson, G. (2012). Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-12-0343

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.